Kazia Therapeutics
KZIA
Kazia Therapeutics (KZIA) news
Recent news
Kazia Therapeutics announces Sovargen Co. doses first patient in phase 1B/2A trial of Paxalisib for rare seizure disorders
AInvest Wire · Sep 22, 2026Kazia Therapeutics announces first patient dosed in PNOC035 clinical study evaluating Paxalisib for recurrent pediatric at/rt brain cancer
AInvest Wire · Sep 9, 2026Kazia Therapeutics - Phase 2 trial enrollment expected to begin Q1 2027, full enrollment by end of 2027
AInvest Wire · Sep 1, 2026Kazia Therapeutics - Plans five-arm phase 2 trial of Paxalisib monotherapy and combination with pembrolizumab
AInvest Wire · Sep 1, 2026Kazia Therapeutics - To advance Paxalisib into phase 2 study for immunotherapy-resistant MSS/PMMR colorectal cancer
AInvest Wire · Sep 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.